Biomarker Analysis Contextualizes RFS Benefit With Nivolumab in Metastatic Melanoma
September 1st 2023Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
Read More
CAR T-Cell Therapy Innovations Unfold Across the Spectrum of Cancer Care
August 31st 2023Martin E. Gutierrez, MD, and Lori A. Leslie, MD, discuss common barriers to implementing CAR T-cell therapy programs, early successes that John Theurer Cancer Center in New Jersey has seen with outpatient CAR T-cell therapy administration, and developments on the horizon for administering this approach in solid tumors
Read More
VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium
August 25th 2023Qian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cell therapy in patients with solid tumors.
Read More
Novel Bispecific ADC Generates Early Efficacy Signals in Lung and Head and Neck Cancers
August 24th 2023Pasi A. Jänne, MD, PhD, discusses the advantages of bispecific ADCs that target both HER3 and EGFR; preliminary efficacy and safety data seen with BL-B01D1 in patients with non–small cell lung cancer; and the activity of this agent in patients with head and neck squamous cell carcinoma, small cell lung cancer, and nasopharynx cancer.
Read More
TROP2 Expression Predicts Sacituzumab Govitecan Activity in Recurrent Endometrial Cancer
August 24th 2023Alessandro Santin, MD, discusses the rationale and design of a phase 2 trial of sacituzumab govitecan in patients with persistent or recurrent endometrial cancer; unmet needs for patients with this disease; and key findings from the stage 1 portion of the trial.
Read More
Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast Cancer
August 22nd 2023Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.
Read More
Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies
August 18th 2023Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.
Read More
Tazemetostat Plus Lenalidomide and Rituximab Under Investigation in R/R Follicular Lymphoma
August 17th 2023Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.
Read More
Molecular Subtyping and Surgical Sequencing Broaden Immunotherapy Applications in RCC
August 14th 2023Tian Zhang, MD, discusses unanswered questions regarding molecular drivers of kidney cancer that the OPTIC RCC trial aims to answer, next steps with this research, and the potential benefits of receiving systemic therapy prior to undergoing cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.
Read More
Tirabrutinib Generates Sustained Efficacy in Relapsed/Refractory PCNSL
August 11th 2023Treatment with the second-generation BTK inhibitor tirabrutinib continued to elicit durable responses in patients with relapsed/refractory primary central nervous system lymphoma, according to findings from the final 3-year analysis of a phase 1/2 trial.
Read More
Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
August 10th 2023Hans Lee, MD, discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and how these data may inform the future of the multiple myeloma treatment paradigm.
Read More
Novel PROTACs Broaden the HR+ Breast Cancer Investigational Landscape
August 9th 2023Seth Wander, MD, PhD, discusses evidence to support the investigation of PROTACs in patients with hormone receptor–positive breast cancer; preliminary efficacy and safety findings with vepdegestrant; and potential strategies for targeting acquired ESR1 resistance mutations.
Read More
Expanding Breast Cancer Armamentarium Is Increasing the Quality of Individualized Care
August 8th 2023Michelina Cairo, MD, discusses key insights from trials including SONIA and CAPItello-291; how adverse effects inform treatment decisions across the breast cancer spectrum; and where the future is headed for ADCs and oral SERDs in patients with breast cancer.
Read More
MRIdian-Guided Radiation Therapy Is Safe and Effective in Patients With Cancer
August 7th 2023Michael D. Chuong, MD, discusses the role of MRI-guided radiation therapy in pancreatic cancer and other solid tumors; the benefits of the MRIdian system; and future directions regarding MRIdian operation training and research investigating this approach in combination with chemotherapy.
Read More
ADCs, CDK4/6 Inhibitors, and SERDs Broaden HR+ and Triple-Negative Breast Cancer Treatment Paradigms
August 4th 2023Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease.
Read More
Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts
August 3rd 2023Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.
Read More
Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer
August 2nd 2023Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.
Read More
Wealth of BTK Inhibitors Provides Tolerable, Individualized Treatment Options in CLL and MCL
August 2nd 2023Prioty Islam, MD, MSc, reviews the benefits of using covalent BTK inhibitors in CLL and MCL; considerations for choosing first-generation vs next-generation covalent BTK inhibitors in patients with these B-cell malignancies; and the potential future role for ibrutinib in the CLL treatment paradigm.
Read More
Talquetamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
August 2nd 2023Carolina D. Schinke, MD, discusses key efficacy findings from the MonumenTAL-1 trial, adverse effects to be aware of with talquetamab, and what the findings from this trial reveal about the potential future for talquetamab and other bispecific antibodies in patients with multiple myeloma.
Read More
Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL
August 1st 2023Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.
Read More
Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population
July 28th 2023Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.
Read More
Uproleselan Plus SOC Targeted Regimens and Chemotherapy Under Investigation in AML
July 28th 2023Bhavana “Tina” Bhatnagar, DO, discusses the mechanism of action of uproleselan, the potential efficacy and safety benefits of adding this agent to standard therapeutic regimens in patients with AML, and the importance of considering MRD negativity as an end point in AML clinical trials.
Read More
Phase 2 Data Indicate Role of Tovorafenib in Pediatric Low-Grade Glioma
July 27th 2023Sarah E. S. Leary, MD, MS, spotlights the importance of developing effective treatments for pediatric patients with low-grade glioma, key findings with tovorafenib in patients with RAF mutations, and how this agent may influence the low-grade glioma therapeutic landscape going forward.
Read More
Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer
July 26th 2023Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Read More
Treatment Sequencing Clarifications May Spur NSCLC Therapeutic Evolutions
July 25th 2023Angel Qin, MD, contextualizes the non–small cell lung cancer ADAURA trial, in which patients with EGFR-mutated non–small cell lung cancer who received adjuvant therapy with osimertinib achieved a 5-year overall survival rate of 85% vs 73% in those who received placebo.
Read More
GI Cancer Research Lends Insight Into the Future of Chemotherapy Combinations and Sequencing
July 24th 2023Mark Lewis, MD, discusses the contested designs of the NorPACT-1 trial and NAPOLI 3 trial; where trastuzumab deruxtecan falls in the HER2-positive metastatic colorectal cancer treatment paradigm; and how the PROSPECT trial results can improve quality of life for patients with rectal cancer.
Read More
Diagnostic Advances Distinguish Actionable Drivers of Early Progression in ER+ Breast Cancer
July 19th 2023Ahmed Elkhanany, MD discusses unmet needs in patients with estrogen receptor–positive breast cancer who progress on frontline therapy, treatment considerations for these patients, and how FES PET imaging may benefit this population.
Read More
Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL
July 19th 2023Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.
Read More